Dean Slagel, Director at Cara Therapeutics, Inc. (CARA), sold 500,000 shares at $25.81 ($12.9M) on 2017-06-29, disclosed to the SEC on 2017-07-03.
Open-market sale of $12.9M CARA by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.81 | 229,138 | $5.9M | 45.7% |
| 2 | $25.81 | 229,138 | $5.9M | 45.7% |
| 3 | $26.58 | 20,862 | $555K | 4.3% |
| 4 | $26.58 | 20,862 | $555K | 4.3% |
| Total | $25.87 avg | 500,000 | $12.9M | 100% |
| Filing → |